Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

Labcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies Supports access to targeted treatment options for the deadliest form of skin cancer BURLINGTON, N.C., Aug. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.

PRNewsWire • Aug 10, 2026

Here's Why Labcorp Holdings (LH) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 10, 2026

Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?

LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.

Zacks Investment Research • Aug 10, 2026

Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation

LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.

Zacks Investment Research • Aug 7, 2026

Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.

PRNewsWire • Aug 4, 2026

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Aug 4, 2026

Labcorp Q2 Earnings Call Highlights

Labcorp NYSE: LH reported second-quarter 2026 revenue growth, margin expansion and higher adjusted earnings, prompting the laboratory services company to raise the midpoint of its full-year revenue and adjusted EPS guidance.

MarketBeat • Jul 31, 2026

Labcorp raises annual profit forecast on strong testing demand

Laboratory operator Labcorp raised its annual profit ​forecast and posted better-than-expected second-quarter results on Thursday, as steady demand ‌for diagnostic testing and growth in its drug-development services business boosted performance.

Reuters • Jul 30, 2026

Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance

Results from operations for second quarter 2026 versus second quarter 2025: Revenue: $3.73 billion vs. $3.53 billion, up 5.8% Diluted EPS: $3.64 vs.

PRNewsWire • Jul 30, 2026

LH Stock Down Despite Q2 Earnings and Revenue Beat, Margins Rise

Labcorp's Q2 earnings and revenues surpass estimates, margins expand, and its 2026 outlook is raised, but shares fall 6% in pre-market trading.

Zacks Investment Research • Jul 30, 2026